Full-Time

Associate Director Content Studio Technology Lead

Medical Affairs

Updated on 9/10/2026

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$177.9k - $253.2k/yr

+ Discretionary annual bonus + Discretionary stock-based long-term incentives

Company Historically Provides H1B Sponsorship

Foster City, CA, USA + 1 more

More locations: Parsippany-Troy Hills, NJ, USA

Hybrid

On-site at least 3 days per week in Foster City or Parsippany.

Bachelor's, Master's, MBA

Category
Creative Production (1)
Required Skills
LLM
Quality Assurance (QA)
Version Control
HTML/CSS

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • A Master's degree and 8 years of experience, or a Bachelor's degree and 10 years of experience, in medical content production, digital content operations, creative production management, or related fields.
  • Familiarity with Medical Affairs content types, HTML content authoring, and digital content production in a professional or agency environment.
  • Familiarity with content management and digital asset management platforms used in pharmaceutical or life sciences organizations.
Responsibilities
  • Own and operate the content production function as a managed service for Medical Affairs, delivering email content, web assets, dynamic HTML-based interactive content, and multi-format deliverables on time and to quality standards.
  • Manage intake, prioritization, and capacity planning for content production requests across multiple therapeutic areas and stakeholder groups.
  • Define and maintain production standards, quality gates, and review processes that ensure content meets brand, regulatory, and compliance requirements before delivery.
  • Build and maintain production service-level agreements, turnaround benchmarks, and reporting dashboards that provide visibility into throughput, quality, and capacity.
  • Create a culture of product excellence and operational rigor within the production team.
  • Partner with Medical Affairs and Medical Content Strategy to translate content strategy, format vision, and technology direction into production-ready workflows.
  • Manage and develop a team of content producers responsible for HTML authoring, email builds, interactive content development, and asset adaptation across formats and channels.
  • Partner with design agencies to translate creative briefs and mockups into production-ready, compliant digital content and manage the handoff from design to build.
  • Design and build the future-state offshore content production capability, including processes, training, quality assurance, and governance for global-to-local and local-to-global content derivative workflows.
  • Evaluate, implement, and operationalize artificial intelligence-powered content authoring and production tools.
  • Identify production workflow opportunities where artificial intelligence can reduce manual effort, improve consistency, or enable new content formats.
  • Partner with the Global AI Technology Capability Lead to align adopted artificial intelligence tools with the Medical Affairs artificial intelligence governance framework and compliance requirements.
  • Build artificial-intelligence-assisted production workflows for content derivatives, local-market adaptation, and multi-format deliverables.
  • Stay current on emerging artificial intelligence content production tools and generative design capabilities and recommend what to adopt, pilot, or monitor.
  • Own product direction for content authoring and production platforms, ensuring they are configured, performant, and aligned with production workflows.
  • Define and evolve the production technology stack, including HTML authoring tools, asset management systems, template frameworks, and quality assurance tooling.
  • Drive platform improvements and integrations connecting authoring tools with review and approval systems, digital asset management, and downstream delivery channels.
  • Ensure production infrastructure supports global-to-local derivative workflows with traceability and version control.
  • Partner with Medical Affairs, Medical Content Strategy and Enablement, Insights Data and Analytics, and content technology teams to align production platforms with the content vision and technology roadmap.
  • Create inclusion, develop talent, and empower teams through team management, coaching, feedback, goal alignment, and barrier removal.
Desired Qualifications
  • Experience leading a content production or digital content operations team, managing workload, digital content standards, quality standards, agency partnerships, and team development.
  • Deep expertise in HTML authoring, responsive email development, dynamic and interactive digital content creation, and modern web content production techniques.
  • Experience evaluating and implementing artificial intelligence-powered content tools, including generative artificial intelligence for content creation, automated adaptation, and intelligent production workflows.
  • A track record of running content production as a managed service with defined service-level agreements, intake processes, quality gates, and throughput reporting.
  • Experience building or managing offshore or distributed content production capabilities, including process design, training, quality assurance, and governance for global-to-local content derivative workflows.
  • Experience partnering with design agencies, managing the creative-to-production handoff, and aligning agency partners on quality and delivery standards.
  • Understanding of regulatory and compliance requirements for Medical Affairs content, including review and approval workflows, fair balance, and promotional versus non-promotional content distinctions.
  • Pharmaceutical or life sciences experience; candidates from healthcare, publishing, or media with deep content production and artificial intelligence backgrounds will also be considered.
  • Strong project management skills for managing multiple concurrent production workstreams across teams, agencies, and time zones.
  • A creative production mindset paired with operational discipline, balancing output quality with process efficiency.
  • Ability to build inclusive, high-performing cultures where team members are supported, challenged, and empowered to grow.
  • An MBA or advanced degree.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $7.8 billion, driven by HIV and oncology.
  • Yeztugo and Descovy lifted Gilead's PrEP franchise above $1 billion quarterly sales.
  • California Supreme Court ruled for Gilead on TDF litigation August 3, 2026.

What critics are saying

  • Bixlenvo's $4,595 monthly list price invites payer pushback and formulary restrictions in 2026.
  • The Arcellx acquisition triggered 192 layoffs, signaling costly integration across 2026-2027.
  • HIV patent battles remain active after CDC-heritage disputes and activist scrutiny in 2026.

What makes Gilead Sciences unique

  • Lenacapavir anchors Gilead's HIV platform across PrEP, treatment, and weekly oral regimens.
  • Bixlenvo, approved August 27, 2026, simplifies complex HIV regimens into one tablet.
  • Trodelvy now holds first-line TNBC approvals in the U.S. and EU.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Sep 5th, 2026
Gilead Sciences secures third FDA approval in 4 months as stock rises 21%

Gilead Sciences has secured three FDA approvals in four months, boosting its shares by over 21% this year. The most recent approval, on 27 August, was for Bixlenvo, a daily pill treating virologically suppressed adults with HIV. Previously, Trodelvy received two approvals for triple-negative breast cancer on 24 June, and Hepcludex gained accelerated approval for chronic hepatitis delta virus infection on 22 May. Additional approvals are expected, including anito-cel for multiple myeloma by year-end and Yeztugo for HIV pre-exposure prophylaxis in February. Gilead reported $7.6 billion in second-quarter revenue, up 8% year over year, with adjusted earnings per share of $2.27, up 13%. The company raised its quarterly dividend by 3.8% to $0.82, marking 11 consecutive years of increases. Its dividend yield stands at 2.15%.

Yahoo Finance
Sep 4th, 2026
Gilead wins FDA approval for Bixlenvo, first single-tablet HIV treatment for complex regimens

Gilead Sciences has received US FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens. The company also secured European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. Bixlenvo is the first single tablet option for complex HIV regimens. The approvals expand Gilead's presence in HIV and oncology, targeting hard-to-treat populations with simplified treatment options. The company's narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029. However, investors face concerns about pricing pressure and execution risk around new launches. The most optimistic analysts forecast revenue of about $38.1 billion and earnings of roughly $12.7 billion by 2029.

American Market News
Sep 4th, 2026
AXQ Capital LP Makes New $3.42 Million Investment in Gilead Sciences, Inc. $GILD

AXQ Capital LP acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, Holdings Channel reports. The firm acquired 27,106 shares of the biopharmaceutical company’s stock, valued at approximately $3,425,000. A number of other hedge funds have also made changes to their positions in the business. Strategic Investment Solutions […]

GlobeNewswire
Sep 3rd, 2026
Eikon Therapeutics appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer.

Eikon Therapeutics appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin ("CP") Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicine, foundational research, and drug discovery. He joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology. "CP is an exceptional physician-scientist whose pioneering basic research in developmental genetics and cardiomyopathies while a student, post-doctoral fellow, and faculty member at Stanford University led to leadership roles in the biopharmaceutical industry, where he demonstrated an ability to translate deep insights about human disease biology into transformative therapies," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer of Eikon Therapeutics. "His scientific judgment, translational expertise, and experience building high-performing research organizations will be invaluable as we apply our differentiated discovery capabilities to create important new medicines." Prior to joining Bristol Myers Squibb, Dr. Chang served as Head of Cardiovascular Research at Gilead Sciences and then as Vice President of Disease Biology at MyoKardia, where he built a disease biology program focused on understanding and targeting the genetic causes of cardiomyopathies and the characterization of mavacamten, which was later approved for the treatment of hypertrophic cardiomyopathy. "It's an honor to join Eikon and work alongside leaders who have helped develop some of the most important medicines of our time," said Dr. Chang. "This is an exciting moment for the company as its late-stage portfolio advances and technology and AI opens new possibilities across drug discovery and development. With its ability to generate novel biological data at exceptional scale, Eikon is well positioned to capitalize on these advances and bring breakthrough therapeutics to patients with serious illnesses." In addition to his industry experience, Dr. Chang built an accomplished academic career centered on developmental genetics, especially as related to cardiomyopathies. He established his own laboratory at Stanford to study genetic, epigenetic, and RNA-based mechanisms underlying abnormal cardiovascular development and heart failure. He later moved his laboratory to Indiana University School of Medicine where he held the Charles Fisch Endowed Chair of Cardiology and also directed Molecular and Translational Medicine at the Krannert Institute of Cardiology. Dr. Chang completed his medical degree at National Taiwan University before moving to the United States, where he earned his Ph.D. in cancer biology at Stanford University, focusing on molecular interactions between protooncogenes and oncogenic mechanisms. He went on to complete medical residency training at Massachusetts General Hospital, a cardiology fellowship at Stanford University, and a physician-scientist research fellowship at the Howard Hughes Medical Institute, a training arc that grounded him both in clinical practice and in fundamental research. About Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com. Forward-Looking/Safe Harbor Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon's product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond; and other statements regarding Eikon's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. These forward-looking statements are based upon management's current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption "Risk Factors" and elsewhere in Eikon's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission ("SEC") on August 13, 2026, and in other public filings with the SEC in the future. As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law. Investors Alfred "Freddie" Bowie, Ph.D., CFO [email protected]

Yahoo
Aug 31st, 2026
A new once-daily pill to treat HIV just got the FDA's green light.

A new once-daily pill to treat HIV just got the FDA's green light. Desiree Guerrero Mon, August 31, 2026 at 1:31 PM PDT On Thursday, the Food and Drug Administration announced it has approved a new once-daily, single-pill HIV treatment, according to a report by CNBC. The new pill, called Bixlenvo and created by Gilead Sciences, is an especially exciting development for people living with HIV because it provides them with another treatment option that contains a minimal amount of drugs. It combines bictegravir, the active ingredient in Gilead's super successful HIV treatment Biktarvy, with lenacapavir, a capsid inhibitor that has become a key component in Gilead's HIV treatment and prevention methods. The new treatment is aimed at individuals whose HIV is already under control but who are still dealing with complicated treatment regimens. The FDA's approval makes it the first single-pill regimen available for HIV+ adults whose virus is suppressed but who, for various reasons, are unable to use any of the single-pill treatments currently on the market, as noted in Gilead's announcement. This represents about five percent of people living with HIV in the U.S. This group is mostly comprised of older individuals with long treatment histories, says Dr. Jared Baeten, Gilead's clinical development and virology therapeutic area head. He notes that many of these people "had to take handfuls of pills around 25 years ago," in addition to the fact that HIV can accelerate other complications of aging, like heart disease, diabetes, and high cholesterol. "It fulfills an unmet need, particularly for individuals who are on complex regimens who just would not otherwise consolidate down to something really meaningful for them and prescribers," Baeten told CNBC. "But it's also meaningful for individuals who are seeking options for something new," he added, commenting on its viability as a treatment option for others outside of this demographic. "We want to build options that give people the opportunity to choose something that's going to work for them and work for them for the long haul." Before discounts or rebates, the list price of Bixlenvo is $4,595 for a one-month supply, which is similar to other daily single-pill treatments. Those without health coverage may be eligible to receive it for free through Gilead's patient assistance program, and people with insurance may be eligible for copay support. Timothy Cameron, a retired Seattle resident who participated in the first Phase 3 trial, also spoke to CNBC about the exciting development. Cameron, 64, has been living with HIV for more than 40 years. He says when he was first diagnosed in the 1980s, very few treatment options existed, and it was difficult for doctors to measure exactly how active the virus. He was prescribed various HIV treatments over the years, including experimental drugs and multi-pill regimens that often came with serious side effects. However, they all would eventually cease to control his "hard-to-treat" HIV. "It was just like throwing darts at a dartboard," Cameron said. "Because I had done so many drug trials and monotherapy, my virus had become super resistant." Fortunately, he survived those difficult years and finally found a regimen that controlled his HIV, but it required him to take a pill twice a day along with another drug. Then a few years ago, his doctor encouraged him to join the trial and switch to Bixlenvo. Cameron says the transition was seamless and the new regimen has maintained control of his HIV without any notable side effects. Switching to the once-daily pill "smaller than my pinky nail" was a welcome relief after decades of treatment struggles "It's one less thing I'm putting in my body, and it preserves options if I need them," Cameron said.